Immunotherapy and targeted therapy before surgery for oral cancer
Part of Cancer, Mouth & dental clinical trials.
This study tests a combination of an immunotherapy drug (Benmelstobart), a targeted therapy (Anlotinib), and standard chemotherapy given before surgery for advanced oral cancer. The goal is to see if this approach can shrink the tumor and improve outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 18 and 75 years old.
- You must have untreated oral cancer that is stage III or IVb and confirmed by biopsy.
- You should be in generally good health (able to do daily activities without help).
- If you could become pregnant, you must use reliable birth control during and for 8 weeks after treatment; men must also use contraception.
- You cannot have had prior immunotherapy (like PD-1 or PD-L1 drugs) or have certain bleeding or clotting disorders.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests giving a combination of targeted immunotherapy and chemotherapy before surgery for people with advanced head and neck cancer (stage 3 or 4a). The goal is to see if this pre-treatment can shrink tumors and improve outcomes.
This study tests two medications given before surgery to shrink mouth cancer and improve outcomes. It is for people with a certain type of mouth cancer that has not been treated yet and can be removed with surgery.
This trial tests a combination of two drugs—an immunotherapy (PD-1 inhibitor) and a targeted therapy (cetuximab)—given before surgery to shrink advanced head and neck cancers. The goal is to see if this approach can lower the risk of the cancer coming back.
This Phase 2 study tests medicines given before surgery for stage III/IV oral squamous cell carcinoma, choosing the treatment based on your tumor marker results. It aims to shrink the cancer and improve outcomes by using two targeted types of therapy.
This trial tests a new immunotherapy drug (tirellizumab) combined with chemotherapy before surgery for early-stage oral cancer. It aims to see if this combination can help shrink the tumor and improve outcomes.
This trial tests two medicines given before lung cancer surgery: benmelstobart (an immunotherapy that helps your immune system fight cancer) and anlotinib (a targeted therapy that stops blood vessel growth to tumors). The goal is to see if they make the cancer disappear completely by the time of surgery.
Hear when a new Mouth Neoplasms trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.